After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's StudyBenzinga • 10/08/24
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer's TreatmentBarrons • 10/08/24
Sage Therapeutics' stock slides after biotech says it will cease development of Alzheimer's treatmentMarket Watch • 10/08/24
SAGE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 10/08/24
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's DiseaseBusiness Wire • 10/08/24
Investors who lost money on Sage Therapeutics, Inc. (SAGE) should contact Levi & Korsinsky about pending Class Action - SAGEAccesswire • 10/07/24
Shareholders that Lost Money on Sage Therapeutics, Inc. (SAGE) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreAccesswire • 10/07/24
Shareholders that lost money on Sage Therapeutics, Inc. (SAGE) should contact Levi & Korsinsky about pending Class Action - SAGEAccesswire • 10/07/24
SAGE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 10/07/24
October 28, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SAGEPRNewsWire • 10/07/24
ROSEN, A RANKED AND LEADING FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGEGlobeNewsWire • 10/06/24
SAGE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 10/06/24
Sage Therapeutics, Inc. Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law FirmAccesswire • 10/05/24
SAGE REMINDER – Robbins LLP Urges SAGE Investors to Obtain Legal Counsel in Light of the Pending Lead Plaintiff DeadlineGlobeNewsWire • 10/05/24
ROSEN, LEADING INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGEGlobeNewsWire • 10/03/24
Levi & Korsinsky Notifies Shareholders of Sage Therapeutics, Inc. (SAGE) of a Class Action Lawsuit and an Upcoming DeadlineAccesswire • 10/02/24
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seeking Recovery for Investors – Contact The Gross Law FirmGlobeNewsWire • 10/02/24
The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against Sage Therapeutics IncAccesswire • 10/02/24
Sage Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights – SAGEAccesswire • 10/01/24
Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Encouraged To Reach Out To The Schall Law FirmAccesswire • 10/01/24
Lost Money on Sage Therapeutics, Inc. (SAGE)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyAccesswire • 10/01/24
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seeking Recovery for Investors – Contact Levi & KorsinskyAccesswire • 10/01/24
Investors who Lost Money on Sage Therapeutics, Inc. (SAGE) Should Contact Levi & Korsinsky About Pending Class Action - SAGEAccesswire • 09/30/24
